– Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 –
– First-in-human study for UBX1325 in age-related eye disease expected to commence in 2H 2020 –SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today provided updates on its lead development programs.Investors
Endurance Advisors
Mike Zanoni
[email protected]  Media
Canale Communications
Jason Spark
[email protected]

Bay Street News